MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 564744 | Name: Vortioxetine free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vortioxetine, also known as Lu AA21004, is an atypical antidepressant, and was approved in 2013 by the U.S. FDA for the treatment of major depressive disorder (MDD) in adults. Vortioxetine is a so-called "serotonin modulator and stimulator." It has been shown to possess the following pharmacological actions: Serotonin transporter (SERT) blocker (i.e. serotonin reuptake inhibitor (SRI)) — Ki (binding affinity) = 1.6 nM, IC50 = 5.4 nM; Norepinephrine transporter (NET) blocker — Ki = 113 nM; 5-HT1A receptor high-efficacy partial agonist/near-full agonist — Ki = 15 nM, IA = 80%; 5-HT1B receptor partial agonist — Ki = 33 nM; 5-HT1D receptor antagonist — Ki = 54 nM; 5-HT3A receptor antagonist — Ki = 3.7 nM; 5-HT7 receptor antagonist — Ki = 19 nM.

Chemical Structure

Vortioxetine free base
Vortioxetine free base
CAS#508233-74-7 (free base)

Theoretical Analysis

MedKoo Cat#: 564744

Name: Vortioxetine free base

CAS#: 508233-74-7 (free base)

Chemical Formula: C18H22N2S

Exact Mass: 298.1504

Molecular Weight: 298.45

Elemental Analysis: C, 72.44; H, 7.43; N, 9.39; S, 10.74

Price and Availability

Size Price Availability Quantity
500mg USD 250.00 2 Weeks
1g USD 400.00 2 weeks
2g USD 650.00 2 weeks
5g USD 1,250.00 2 weeks
10g USD 1,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
960203-27-4 (HBr) 508233-74-7 (free base) 1253056-29-9 (lactate)
Synonym
LuAA21004; LuAA 21004; LuAA-21004; Lu-AA21004; Lu AA21004; AA21004; AA-21004; AA 21004; Vortioxetine; Brintellix.
IUPAC/Chemical Name
1-[2-(2,4-Dimethylphenyl)sulfanylphenyl]piperazine
InChi Key
YQNWZWMKLDQSAC-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
SMILES Code
CC1=CC=C(SC2=CC=CC=C2N3CCNCC3)C(C)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 298.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Berardelli I, Rogante E, Formica F, Iannazzo R, Mammoliti AV, Riccioni R, Veizi S, McIntyre RS, Pompili M. The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis. J Psychopharmacol. 2025 Feb 1:2698811241309612. doi: 10.1177/02698811241309612. Epub ahead of print. PMID: 39891526. 2: Truong J, Abu-Suriya N, Tory D, Bahho R, Ismaiel A, Nguyen T, Mansour A, Nand V, Saponja J, Dua K, De Rubis G, Parisi D. An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics. Eur J Drug Metab Pharmacokinet. 2025 Jan 27. doi: 10.1007/s13318-024-00928-x. Epub ahead of print. PMID: 39870954. 3: Dai C, Fu Y, Li X, Lin M, Li Y, Li X, Huang K, Zhou C, Xie J, Zhao Q, Hu S. Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression. J Zhejiang Univ Sci B. 2025 Jan 15;26(1):26-38. doi: 10.1631/jzus.B2400470. PMID: 39815608; PMCID: PMC11735911. 4: Erkilinc G, Ozdamar G, Ozmen O, Yüceer RO. Effect of vortioxetine and fluoxetine on immunohistochemical expression of Caspase-8, RANKL, and IL-6 in testicular tissue in an experimental depression model. Biotech Histochem. 2025 Jan 15:1-9. doi: 10.1080/10520295.2024.2448489. Epub ahead of print. PMID: 39812418. 5: Verrienti G, Colonna I, Raccagni C. Use of vortioxetine in different neurological fields: a systematic review and future perspectives. Neurol Sci. 2025 Jan 14. doi: 10.1007/s10072-025-07987-1. Epub ahead of print. PMID: 39808348. 6: Akyuz Cim EF, Suleyman Z, Suleyman H, Yazici GN, Coban TA. Effect of Sertraline and Vortioxetine on Stress-Induced Brain Injury in Rats: Biochemical and Histopathological Evaluations. Clin Neuropharmacol. 2024 Nov-Dec 01;47(6):213-217. doi: 10.1097/WNF.0000000000000615. PMID: 39792536. 7: Tamura JK, Harangi D, Rodrigues NB, Mansur RB, Subramaniapillai M, Johnson DE, Rosenblat JD, Lee Y, Di Vincenzo JD, Ho R, Sukhdeo R, Cao B, Lui L, Ceban F, McIntyre RS. [The mediational role of cognitive function on occupational outcomes in persons with major depressive and bipolar disorder]. CNS Spectr. 2025 Jan 10:1-8. French. doi: 10.1017/S1092852924002293. Epub ahead of print. PMID: 39789718. 8: Manter MA, Birtwell KB, Bath J, Friedman NDB, Keary CJ, Neumeyer AM, Palumbo ML, Thom RP, Stonestreet E, Brooks H, Dakin K, Hooker JM, McDougle CJ. Pharmacological treatment in autism: a proposal for guidelines on common co- occurring psychiatric symptoms. BMC Med. 2025 Jan 7;23(1):11. doi: 10.1186/s12916-024-03814-0. PMID: 39773705; PMCID: PMC11705908. 9: Cheng Y, Chen Y, Zhao X, Mou F, Tan Y, Wang W, Qian R, Xu Q, Yu S. The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system. Expert Opin Drug Saf. 2024 Dec 23:1-11. doi: 10.1080/14740338.2024.2443956. Epub ahead of print. PMID: 39693256. 10: Chung AKK, Tse CY, Yeung GKY, Tang SW, Chan WM, Law JKC. Vortioxetine improves illness severity for cannabis users with anxiety and depressive symptoms in a 6-month randomized controlled study. J Subst Use Addict Treat. 2025 Feb;169:209607. doi: 10.1016/j.josat.2024.209607. Epub 2024 Dec 12. PMID: 39672338. 11: Ye X, Xu P, Jiao J, Zhao H, Jin K, Zhang S, Pan F, Chen J, Jiang H, Hu J, Huang M. A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality. Neuropsychiatr Dis Treat. 2024 Dec 5;20:2363-2374. doi: 10.2147/NDT.S491768. PMID: 39654656; PMCID: PMC11626980. 12: Kim HC. Short-Term Risk of Type 2 Diabetes in Patients Using Various Antidepressants Compared with Patients Using Fluoxetine. Psychiatry Clin Psychopharmacol. 2024 Nov 28;34(4):294-301. doi: 10.5152/pcp.2024.24917. PMID: 39629756; PMCID: PMC11744381. 13: Lee LE, Chung KH. Vortioxetine-Induced Bleeding Tendency in a Young Woman with Depression: A Case Report. Psychiatry Clin Psychopharmacol. 2024 Nov 28;34(4):353-355. doi: 10.5152/pcp.2024.24927. PMID: 39629743; PMCID: PMC11744379. 14: Moon SW, Kim JW, Kim DH, Adair M, Åström DO, Reines EH, Lee M, Kim G. Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea. Neuropsychiatr Dis Treat. 2024 Nov 26;20:2299-2311. doi: 10.2147/NDT.S478804. PMID: 39619493; PMCID: PMC11608001. 15: Zhang K, Feng W, Mou Z, Zhang L, Ma M, Zhao Z, Liu X, Chen X, Li Z. Late- stage (radio)fluorination of alkyl phosphonates via electrophilic activation. Nat Commun. 2024 Nov 28;15(1):10338. doi: 10.1038/s41467-024-54208-y. PMID: 39609392; PMCID: PMC11604993. 16: Zeraatkar D, Ling M, Kirsh S, Jassal T, Shahab M, Movahed H, Talukdar JR, Walch A, Chakraborty S, Turner T, Turkstra L, McIntyre RS, Izcovich A, Mbuagbaw L, Agoritsas T, Flottorp SA, Garner P, Pitre T, Couban RJ, Busse JW. Interventions for the management of long covid (post-covid condition): living systematic review. BMJ. 2024 Nov 27;387:e081318. doi: 10.1136/bmj-2024-081318. PMID: 39603702; PMCID: PMC11600537. 17: Furutani N, Nagoshi Y. Vortioxetine as an alternative treatment for somatic symptom disorder: case report. Front Psychiatry. 2024 Nov 7;15:1496072. doi: 10.3389/fpsyt.2024.1496072. PMID: 39575195; PMCID: PMC11578982. 18: Singh P, Agrawal P, Singh KP. Neurocognitive impairments in rat offspring after maternal exposure to vortioxetine: Involvement of BDNF, apoptosis and cholinergic mediated signaling pathways. Reprod Toxicol. 2025 Jan;131:108746. doi: 10.1016/j.reprotox.2024.108746. Epub 2024 Nov 16. PMID: 39557222. 19: Greš A, Šagud M, Dickov A. EFFECT OF VORTIOXETINE ON THE QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA. Psychiatr Danub. 2024 May;36(1):47-57. doi: 10.24869/psyd.2024.47. PMID: 39546512. 20: Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. Revisiting Depression Rating Scales: Analysis of a Randomized Trial. Cureus. 2024 Oct 13;16(10):e71346. doi: 10.7759/cureus.71346. PMID: 39539917; PMCID: PMC11558025.